Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial.
Schwentner L, Harbeck N, Singer S, Eichler M, Rack B, Forstbauer H, Wischnik A, Scholz C, Huober J, Friedl TW, Weissenbacher T, Härtl K, Kiechle M, Janni W, Fink V. Schwentner L, et al. Among authors: fink v. Breast. 2016 Jun;27:69-77. doi: 10.1016/j.breast.2016.03.003. Epub 2016 Apr 4. Breast. 2016. PMID: 27054751 Clinical Trial.
Evaluation of two different analytical methods for circulating tumor cell detection in peripheral blood of patients with primary breast cancer.
Jaeger BA, Jueckstock J, Andergassen U, Salmen J, Schochter F, Fink V, Alunni-Fabbroni M, Rezai M, Beck T, Beckmann MW, Friese K, Friedl TW, Janni W, Rack B. Jaeger BA, et al. Among authors: fink v. Biomed Res Int. 2014;2014:491459. doi: 10.1155/2014/491459. Epub 2014 Apr 8. Biomed Res Int. 2014. PMID: 24800234 Free PMC article. Clinical Trial.
Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review.
Schramm A, De Gregorio N, Widschwendter P, Fink V, Huober J. Schramm A, et al. Among authors: fink v. Breast Care (Basel). 2015 Jul;10(3):173-8. doi: 10.1159/000431029. Epub 2015 Jun 18. Breast Care (Basel). 2015. PMID: 26557822 Free PMC article. Review.
Pretreatment quality of life, performance status and their relation to treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy: results from the prospective randomized ADEBAR trial.
Eichler M, Singer S, Janni W, Harbeck N, Rack B, Augustin D, Wischnik A, Kiechle M, Ettl J, Scholz C, Fink V, Schwentner L. Eichler M, et al. Among authors: fink v. Breast Cancer. 2017 Mar;24(2):319-325. doi: 10.1007/s12282-016-0706-3. Epub 2016 Jun 4. Breast Cancer. 2017. PMID: 27262301 Clinical Trial.
The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
Leinert E, Singer S, Janni W, Harbeck N, Weissenbacher T, Rack B, Augustin D, Wischnik A, Kiechle M, Ettl J, Fink V, Schwentner L, Eichler M. Leinert E, et al. Among authors: fink v. Clin Breast Cancer. 2017 Apr;17(2):100-106. doi: 10.1016/j.clbc.2016.10.008. Epub 2016 Oct 19. Clin Breast Cancer. 2017. PMID: 27884722
Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial.
Cámara RJA, Schwentner L, Friedl TWP, Deniz M, Fink V, Lato K, Widschwendter P, Rack B, Janni W, Singer S, Bekes I. Cámara RJA, et al. Among authors: fink v. Breast Cancer Res Treat. 2019 Jun;175(3):627-635. doi: 10.1007/s10549-019-05171-6. Epub 2019 Mar 21. Breast Cancer Res Treat. 2019. PMID: 30900137 Clinical Trial.
85 results